Stock BAX BAXTER INTERNATIONAL INC.
Add to a list
To use this feature you must be a member
Log inSign up

Financials Baxter International Inc.

Equities

BAX

US0718131099

Medical Equipment, Supplies & Distribution

Market Closed - Nyse
Other stock markets
 16:00:01 2024-04-26 EDT 		5-day change 1st Jan Change
40.13 USD -0.25% Intraday chart for Baxter International Inc. +1.67% +3.80%
04-23 Edwards Lifesciences Corporation: The story continues Our Logo
04-15 Exact Sciences Names Aaron Bloomer CFO MT

Valuation

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Capitalization 1 42,693 40,981 42,980 25,695 19,613 20,440 - -
Enterprise Value (EV) 1 44,708 43,443 57,689 40,613 30,217 29,594 28,463 29,054
P/E ratio 43.3 x 37.7 x 33.9 x -10.6 x 7.36 x 21.3 x 17.8 x 16.9 x
Yield 1.02% 1.19% 1.26% 2.26% 3% 2.88% 3.11% 3.23%
Capitalization / Revenue 3.76 x 3.51 x 3.36 x 1.7 x 1.32 x 1.35 x 1.3 x 1.25 x
EV / Revenue 3.93 x 3.72 x 4.51 x 2.69 x 2.04 x 1.96 x 1.82 x 1.78 x
EV / EBITDA 16.4 x 16.1 x 19.2 x 12.6 x 11.1 x 10.2 x 9.12 x 8.64 x
EV / FCF 31.8 x 37.4 x 39 x 76.3 x 30 x 14.9 x 20.7 x -
FCF Yield 3.15% 2.67% 2.56% 1.31% 3.33% 6.71% 4.82% -
Price to Book 5.37 x 4.77 x 4.74 x 4.41 x 2.33 x 2.22 x 2.05 x 2.05 x
Nbr of stocks (in thousands) 510,556 510,731 500,693 504,121 507,324 509,347 - -
Reference price 2 83.62 80.24 85.84 50.97 38.66 40.13 40.13 40.13
Announcement Date 20-03-17 21-02-04 22-02-17 23-02-09 24-02-08 - - -
1USD in Million2USD
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Net sales 1 11,362 11,673 12,784 15,113 14,813 15,107 15,682 16,342
EBITDA 1 2,726 2,698 3,003 3,233 2,734 2,903 3,122 3,361
EBIT 1 2,120 2,097 2,400 2,583 2,123 2,250 2,441 2,626
Operating Margin 18.66% 17.96% 18.77% 17.09% 14.33% 14.89% 15.56% 16.07%
Earnings before Tax (EBT) 1 970 1,292 1,477 -2,353 -103 1,401 1,567 1,116
Net income 1 1,001 1,102 1,284 -2,433 2,656 747.2 960.5 1,190
Net margin 8.81% 9.44% 10.04% -16.1% 17.93% 4.95% 6.13% 7.28%
EPS 2 1.930 2.130 2.530 -4.830 5.250 1.880 2.258 2.370
Free Cash Flow 1 1,408 1,161 1,479 532 1,007 1,986 1,373 -
FCF margin 12.39% 9.95% 11.57% 3.52% 6.8% 13.14% 8.76% -
FCF Conversion (EBITDA) 51.65% 43.03% 49.25% 16.46% 36.83% 68.4% 43.98% -
FCF Conversion (Net income) 140.66% 105.35% 115.19% - 37.91% 265.76% 142.95% -
Dividend per Share 2 0.8500 0.9550 1.085 1.150 1.160 1.157 1.250 1.296
Announcement Date 20-03-17 21-02-04 22-02-17 23-02-09 24-02-08 - - -
1USD in Million2USD
Estimates

Income Statement Evolution (Quarterly data)

Fiscal Period: December 2021 Q3 2021 Q4 2022 Q1 2022 Q2 2022 Q3 2022 Q4 2023 Q1 2023 Q2 2023 Q3 2023 Q4 2024 Q1 2024 Q2 2024 Q3 2024 Q4 2025 Q1
Net sales 1 3,226 3,514 3,707 3,746 3,773 3,887 3,649 3,707 3,708 3,885 3,551 3,768 3,789 3,991 3,702
EBITDA 1 790 821 829 1,147 815 822 660 798 714 783 648.9 719.2 735.5 828 -
EBIT 1 652 714 666 605 649 663 503 489 565 630 480.6 528.5 584.1 653.5 540.7
Operating Margin 20.21% 20.32% 17.97% 16.15% 17.2% 17.06% 13.78% 13.19% 15.24% 16.22% 13.53% 14.03% 15.42% 16.37% 14.6%
Earnings before Tax (EBT) 1 451 283 94 295 -2,966 224 70 -183 -172 238 410.6 437.8 495.2 567.5 -
Net income 1 450 238 71 252 -2,937 181 44 335 2,508 - 167 225 231.7 264 -
Net margin 13.95% 6.77% 1.92% 6.73% -77.84% 4.66% 1.21% 9.04% 67.64% - 4.7% 5.97% 6.12% 6.61% -
EPS 2 0.8900 0.4700 0.1400 0.5000 -5.830 0.3600 0.0900 0.6600 4.930 0.4800 0.3300 0.4400 0.4500 0.5200 -
Dividend per Share 2 0.2800 0.2800 0.2800 0.2900 0.2900 0.2900 0.2900 0.2900 0.2900 0.2900 0.2889 0.2878 0.2873 0.2868 0.2864
Announcement Date 21-10-28 22-02-17 22-04-28 22-07-28 22-10-27 23-02-09 23-04-27 23-07-27 23-11-02 24-02-08 - - - - -
1USD in Million2USD
Estimates

Balance Sheet Analysis

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Net Debt 1 2,015 2,462 14,709 14,918 10,604 9,154 8,023 8,614
Net Cash position 1 - - - - - - - -
Leverage (Debt/EBITDA) 0.7392 x 0.9125 x 4.898 x 4.614 x 3.879 x 3.153 x 2.57 x 2.563 x
Free Cash Flow 1 1,408 1,161 1,479 532 1,007 1,986 1,373 -
ROE (net income / shareholders' equity) 21.8% 19.3% 20.7% 23.8% 18.6% 16.8% 17.1% 16.8%
ROA (Net income/ Total Assets) 10.1% 8.4% 6.86% 5.73% 4.69% 5.09% 5.9% 7.05%
Assets 1 9,886 13,119 18,722 -42,432 56,606 14,686 16,288 16,873
Book Value Per Share 2 15.60 16.80 18.10 11.60 16.60 18.10 19.60 19.60
Cash Flow per Share 2 4.050 3.620 4.370 2.400 3.410 4.510 4.720 -
Capex 1 696 709 743 679 719 719 747 1,207
Capex / Sales 6.13% 6.07% 5.81% 4.49% 4.85% 4.76% 4.76% 7.38%
Announcement Date 20-03-17 21-02-04 22-02-17 23-02-09 24-02-08 - - -
1USD in Million2USD
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Year-on-year evolution of the Yield

Change in Enterprise Value/EBITDA

Ratings for Baxter International Inc.

Trading Rating
Investor Rating
ESG Refinitiv
C+
More Ratings

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
17
Last Close Price
40.13 USD
Average target price
47.4 USD
Spread / Average Target
+18.12%
Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Medical Equipment, Supplies & Distribution

1st Jan change Capi.
BAXTER INTERNATIONAL INC. Stock Baxter International Inc.
+3.80% 20.44B
ABBOTT LABORATORIES Stock Abbott Laboratories
-2.31% 187B
MEDTRONIC PLC Stock Medtronic plc
-3.20% 106B
BECTON, DICKINSON AND COMPANY Stock Becton, Dickinson and Company
-5.04% 66.9B
DEXCOM, INC. Stock DexCom, Inc.
+0.20% 49.45B
CENCORA, INC. Stock Cencora, Inc.
+17.29% 48B
HOYA CORPORATION Stock Hoya Corporation
+4.06% 40.84B
METTLER-TOLEDO INTERNATIONAL, INC. Stock Mettler-Toledo International, Inc.
+2.07% 26.48B
WEST PHARMACEUTICAL SERVICES, INC. Stock West Pharmaceutical Services, Inc.
+2.36% 26.25B
TERUMO CORPORATION Stock Terumo Corporation
+12.96% 24.62B
Other Medical Equipment, Supplies & Distribution
  1. Stock Market
  2. Equities
  3. BAX Stock
  4. Financials Baxter International Inc.